Kidney disease is one of the most serious complications associated with type 2 diabetes, yet it can progress quietly. A person may feel well while urine albumin changes, estimated glomerular filtration rate (eGFR) declines, blood pressure rises, or cardiovascular risk increases.

That is why early screening and risk assessment matter. They give the care team more time to confirm what is happening, discuss treatment options, and help the person build a plan for kidney, heart, and metabolic health.

A recent announcement from Renalytix highlights new two-year, real-world findings for KidneyIntelX, a blood-based risk-stratification test used in people with type 2 diabetes and early-stage chronic kidney disease. The company’s press release uses emphatic language about the test’s results. The more useful discussion is not whether a headline calls a tool “unprecedented.” It is what the study actually measured, what it can reasonably suggest, and how risk tools should fit into good kidney care.

What the study examined

The peer-reviewed article is titled “Real-World Associations of KidneyIntelX Risk Stratification With Guideline-Directed Therapy, Kidney Outcomes, and Metabolic Trajectories in Early Diabetic Kidney Disease”. The word associations is important.

The research followed 2,470 people with type 2 diabetes and early-stage chronic kidney disease across two U.S. health systems. It examined how KidneyIntelX risk categories related to treatment patterns, kidney measures, metabolic markers, and changes over two years. The company’s announcement reports increased use of SGLT2 inhibitors and GLP-1 receptor agonists after baseline risk assessment, along with changes in eGFR slope, urinary albumin, A1C, and risk categories.

That is clinically interesting. If a team can identify someone at higher risk earlier, it may be more likely to focus attention on kidney-protective treatment, blood pressure, glucose management, cardiovascular risk, and follow-up.

But an observational, real-world study cannot prove that the test itself caused every later improvement. Patients may have received multiple interventions. Clinicians may have already been more attentive. Health systems may have had other protocols in place. And people who were retested may differ from people who were not.

The strongest statement is this: the study reports real-world associations between risk stratification, treatment patterns, and subsequent health markers. It supports further discussion of how risk tools may help teams direct care. It does not establish a guarantee for every patient or prove that one proprietary test is the only way to improve kidney outcomes.

Why risk stratification can still be valuable

Risk stratification is not the same as diagnosis. It does not tell a person exactly what will happen to their kidneys. It helps place the person’s current information into a risk context so a care team can decide where more attention may be needed.

In diabetes care, that can be valuable because “average” care is often not enough. Two people can have the same A1C and very different kidney risk. One may have rising urine albumin, uncontrolled blood pressure, a history of cardiovascular disease, or a faster change in eGFR. Another may have stable measures and need a different level of monitoring or treatment intensity.

The KDIGO 2024 guideline for chronic kidney disease evaluation and management emphasizes structured evaluation and risk-based management of CKD. The American Diabetes Association’s Standards of Care section on chronic kidney disease and risk management provides diabetes-specific guidance on screening, monitoring, and risk reduction.

Those resources are a useful reminder that kidney care is bigger than one score. It involves eGFR, urine albumin, blood pressure, glucose, medication review, cardiovascular health, access to specialists when needed, and the person’s ability to follow a plan over time.

Technology should support clinical judgment—not replace it

Precision medicine can sound like a promise that a blood test or algorithm will make care automatic. In reality, a tool is only useful if it leads to better conversations and better decisions.

For a high-risk result, the right next step may be a review of current treatment, more frequent monitoring, referral to nephrology, or attention to barriers such as medication cost, food access, transportation, or blood-pressure monitoring. For a lower-risk result, the conversation may focus on maintaining progress while staying alert to changes.

Neither result should become a reason to ignore the person in front of the clinician.

This is especially important in diabetes, where “risk” can sound like blame. It is not. Risk information should reduce uncertainty and expand options. It should not make a patient feel that future kidney decline is inevitable or that they have failed.

What readers can do now

You do not need a specialty test to start asking good kidney-health questions. If you live with type 2 diabetes, consider asking your care team:

• How are my eGFR and urine albumin being monitored?
• What do my most recent values mean in the context of my overall health?
• How are my blood pressure, glucose, cholesterol, and cardiovascular risks being addressed?
• Are any medications I take protecting my kidneys, or could any need adjustment because of kidney function?
• What symptoms or test changes should prompt follow-up?
• Would a referral to a kidney specialist or a more detailed risk assessment be useful in my situation?

These are not questions that require someone to buy a particular test. They are part of routine, proactive diabetes care.

Whole-person kidney protection matters

Medication is often important in diabetic kidney disease, and some medicines can have kidney and cardiovascular benefits for the right patient. But medication works within a larger environment.

Blood-pressure monitoring, reduced sodium when appropriate, food patterns that are realistic and nutritious, physical activity that fits a person’s function, sleep, stress management, avoidance of tobacco, regular laboratory follow-up, and help overcoming cost or access barriers can all matter. A kidney-care plan should be medically sound and workable at home.

This is also why study results should not be used to create a false choice between “high-tech precision care” and “lifestyle care.” People deserve both careful medical assessment and practical support for the conditions that shape day-to-day health.

A useful standard: A risk score is most valuable when it opens a better care conversation—not when it closes one with a prediction.

The Diabetes Reversal Group perspective

At Diabetes Reversal Group, we believe protecting kidney health in type 2 diabetes requires early attention, consistent monitoring, and a whole-person plan. Holistic care includes food quality, blood-pressure support, movement, sleep, stress, access to care, regular testing, and medications when clinically indicated. We welcome tools that help care teams see risk earlier, while recognizing that no test replaces the relationship, follow-up, and sustainable habits that help people protect their health.

By: Dr. Jeffrey Hockings, CEO & Founder & Kristine Burke, MD, Chief Medical Officer

Do not interpret a kidney result or change medication on your own. Review it with the clinician managing your diabetes and kidney care.